Massachusetts Weekly
SEE OTHER BRANDS

The most trusted news from Massachusetts

Massachusetts Weekly: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Weekly.

Press releases published on June 30, 2025

Health Product Declaration Collaborative Announces 2025 Board and Technical Committee Leadership

Health Product Declaration Collaborative Announces 2025 Board and Technical Committee Leadership

Leader in Material Health Refreshes Member Leadership with Industry Expertise WAKEFIELD, MA, UNITED STATES, June 30, 2025 /⁨EINPresswire.com⁩/ -- The Health Product Declaration Collaborative (HPDC) today announced its 2025 Board of Directors and 2025-26 …

New Report Finds 56% of Private Equity Domains Vulnerable to Spoofing

New Report Finds 56% of Private Equity Domains Vulnerable to Spoofing

Updated Atumcell Analysis Reveals Modest Progress — and Mounting Cloud-Driven Risks BOSTON, MA, UNITED STATES, June 30, 2025 /⁨EINPresswire.com⁩/ -- Six months after revealing widespread domain spoofing vulnerabilities among private equity (PE) firms, …

CoCountant Expands Industry Focus to Bring Scalable Bookkeeping Expertise to Four High-Growth Industries

CoCountant Expands Industry Focus to Bring Scalable Bookkeeping Expertise to Four High-Growth Industries

Helping healthcare, legal, ecommerce, and supply chain businesses maintain clean books, meet compliance requirements, and scale efficiently. CAMBRIDGE, MA, UNITED STATES, June 30, 2025 /⁨EINPresswire.com⁩/ -- CoCountant, a leading bookkeeping and …

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology’s …

Murder-Suicide: From Sensationalized Headlines  to Untold Survivor Stories

Murder-Suicide: From Sensationalized Headlines to Untold Survivor Stories

BOSTON, MA, UNITED STATES, June 30, 2025 /⁨EINPresswire.com⁩/ -- What links a retired carpenter, an acupuncture expert, a Los Angeles actor, and a community advocate? Not much until the discussion turned to murder-suicide. Mitch Maryanov, Stephanie …

Progress Software Announces Second Quarter 2025 Financial Results

Progress Software Announces Second Quarter 2025 Financial Results

Annualized Recurring Revenue ("ARR") of $838 million Grew 46% year-over-year Revenue of $237 million Grew 36% year-over-year Raises Full Year Guidance for Revenue, Operating Margin, Earnings Per Share, and Cash Flow Acquires Agentic RAG AI Company …

Progress Software Acquires Nuclia, an Innovator in Agentic RAG AI Technology

Progress Software Acquires Nuclia, an Innovator in Agentic RAG AI Technology

Company adds easy-to-use agentic RAG-as-a-service product for organizations to automate and retrieve verifiable, high-quality AI search and generative answers BURLINGTON, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Progress Software (Nasdaq: PRGS), the …

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has …

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

- $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points - WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company …

DraftKings Launches “My Budget Builder” to Enhance Its Responsible Gaming Tools and Resources

DraftKings Launches “My Budget Builder” to Enhance Its Responsible Gaming Tools and Resources

BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- DraftKings Inc. (NASDAQ: DKNG) today announced the launch of My Budget Builder, a new Responsible Gaming (RG) tool that players can use to set customized limits and reminders through a guided, easy-to-use …

Aliaswire Launches Embedded Payment Services for Vertical SaaS Platforms

Aliaswire Launches Embedded Payment Services for Vertical SaaS Platforms

BURLINGTON, Mass., June 30, 2025 (GLOBE NEWSWIRE) --  Aliaswire, provider of DirectBiller®, a market-leading receivables and payment platform serving over 7,000 businesses and millions of end-users, announced the launch of DirectEmbed™ – a comprehensive …

Mimecast Announces Solution to Enhance Data Governance and Compliance Across Collaboration Tools Including Google Workspace

Mimecast Announces Solution to Enhance Data Governance and Compliance Across Collaboration Tools Including Google Workspace

LEXINGTON, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Mimecast, a UK-headquartered global cybersecurity leader transforming the way businesses manage and secure human risk, today announced a new solution with Google Workspace to enhance governance and …

IP Fabric Releases Compliance Mapping Resources for All Major Security & Regulatory Frameworks

IP Fabric Releases Compliance Mapping Resources for All Major Security & Regulatory Frameworks

BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- IP Fabric, the Automated Infrastructure Assurance Platform, today announced new resources to operationalize compliance with leading security frameworks, including NIST and ISO 27001, and regulatory standards, …

Cabot Corporation Achieves Platinum Rating from EcoVadis for Fifth Consecutive Year

Cabot Corporation Achieves Platinum Rating from EcoVadis for Fifth Consecutive Year

BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE: CBT) has earned a platinum rating from EcoVadis, the highest recognition available, for the fifth consecutive year. The platinum rating recognizes Cabot’s environmental, social and …

Microbot Medical® Added to the Russell Microcap® Index

Microbot Medical® Added to the Russell Microcap® Index

HINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it was added as a member of the Russell Microcap® Index. Microbot Medical’s addition …

Tectonic Therapeutic Joins Russell 3000® Index

Tectonic Therapeutic Joins Russell 3000® Index

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of …

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1 MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company …

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN) There are currently no therapies specifically approved for PMN, a rare immune-mediated …

PathAI Receives FDA Clearance for AISight® Dx Platform for Primary Diagnosis

PathAI Receives FDA Clearance for AISight® Dx Platform for Primary Diagnosis

BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx*—its …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service